Health Canada has granted market authorisation to Takeda Canada for FRUZAQLA (fruquintinib) capsules to treat adults with ...

Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and ...

Amgen’s LUMAKRAS and Vectibix combination has received approval from the US FDA for treating KRAS G12C-mutated mCRC.

Colorectal cancer (CRC) ranks third in incidence and second in mortality worldwide. In Ecuador, there are 2,481 new CRC cases per year and 2,366 cancer deaths yearly. CRC presents in stages III-IV in ...

Barry Stein had ignored symptoms that started appearing in 1995, until he was diagnosed with stage four colorectal cancer.

The combination treatment specifically targets KRAS-mutated metastatic colorectal cancer (CRC) to improve progression-free ...

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in ...

The FDA has approved the combination of sotorasib (Lumakras) and panitumumab (Vectibix) for the treatment of patients with ...

The FDA has approved Lumakras with Vectibix for adults with KRAS G12C-mutated metastatic colorectal cancer who received ...

The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...

The possibility of a new therapy for colorectal cancer could be achieved by blocking DUSP6, a protein that is important for ...

A 68-year-old cancer survivor has become the first to conquer remote Pakistan peak alongside his 74-year-old climbing partner despite undergoing life-altering surgery that left him living with a ...